Tefron Follow-Up: The Jordan Transition Economics And Whether The Investment Can Earn Back Margin
Tefron entered 2025 with an unusually heavy investment wave of nearly $20 million around the Jordan transition, but the year-end numbers still do not prove that the move is already earning back margin. For now, this is a thesis about operating potential that still needs to clear a utilization, throughput, and funding test.
This Is Not Routine Upkeep. It Is A Real Operating Bet With A Real Price Tag
The main article argued that retail helped stabilize the top line, but the balance sheet funded the transition year. This follow-up isolates the Jordan move itself, because that is where the real 2026 test sits: did Tefron build a more efficient production base, or did it simply replace a more distributed model with a heavier fixed-cost platform.
The filings show this is not a cosmetic project. The company leased a 34,917 square meter site in Jordan through the end of 2029, with an option for another five years, and said this site is meant to concentrate most of its Jordan production and replace most of its existing Jordan leases. At the same time, the 2025 presentation describes investment in a state-of-the-art facility in Jordan and upgrades to production equipment that are expected to improve manufacturing efficiency and strengthen the competitive position.
That is the core issue. Tefron is not just adding more capacity. It is trying to change the economics of its own manufacturing base: less fragmentation across sites, more concentration, more automation, and likely a push to reduce part of its reliance on subcontractors. If that works, margin can recover. If it does not, the company is left with a larger asset base, longer lease commitments, and financing that already had to stretch to accommodate the move.
What Actually Went Into The Investment Wave
In 2025, net cash used in investing activities reached $19.9 million, versus $9.0 million in 2024. The company says explicitly that the investing outflow mainly reflected payments for machinery and equipment and leasehold improvements at the Jordan factory. Note 8 shows how concentrated that wave really was: $19.255 million of property, plant, and equipment additions, including $9.732 million of machinery and equipment and another $8.726 million of leasehold improvements. In other words, almost all of 2025 fixed-asset investment went straight into the physical core of the transition.
That split matters economically. In 2024, Tefron still looked closer to a regular equipment-refresh cycle. In 2025, the picture changed completely: leasehold improvements jumped from $0.616 million to $8.726 million. That is not maintenance. That is a new operating shell being built.
The balance sheet tells the same story. Non-current assets rose 41.9% to $58.6 million, mainly because of investment in machinery and leasehold improvements related to expanding the self-manufacturing footprint in Jordan. Net book value of property, plant, and equipment rose to $41.3 million from $25.8 million a year earlier. Within that, leasehold improvements climbed to $10.629 million from $2.445 million, and machinery and equipment rose to $28.890 million from $22.038 million.
This is easy to miss: Tefron did not just spend a lot of cash, it materially raised the capital base that now has to earn a return. From here on, the margin test is not only about revenue recovery. It is also about whether the new system can absorb the capital that has already been loaded into it.
The Real Constraint Is Utilization, Not Capacity
Management’s argument is straightforward. Concentrating production in one complex should increase capacity, streamline processes, and reduce production costs. The problem is that through year-end 2025 the operating data still does not show that the bottleneck has been solved.
Knitting capacity stood at 23 million units in both 2024 and 2025. Actual output, however, fell from 15 million units to 13 million, and utilization declined from 65% to 56%. Put simply, Tefron entered its heaviest investment year in recent memory while the existing system was operating well below full absorption.
That does not invalidate the logic of the move. If anything, it helps explain why the company made it. The filing says there are still specific overload periods on the shop floor even when headline capacity looks adequate, and it stresses that knitting sets the pace for the rest of the process. That suggests the issue may not be only how many machines exist, but how the wider chain around them functions: dyeing, sewing, packing, logistics, quality, and the handoff between sites.
But that is also exactly where execution risk lives. If the move is meant to solve a synchronization bottleneck, the payoff has to come through better fixed-cost absorption, less friction between sites, and less waste. If the real problem is primarily weak demand, then the investment does not solve the central problem. It just adds capital intensity on top of it.
Self-Manufacturing Still Has Not Proven Economic Superiority
One of the more interesting disclosures is the gap between the narrative around expanding in-house production and the segment outcome at the end of 2025. In brands, where self-manufacturing is structurally more important, in-house production as a share of segment sales fell to 72% from 76% in 2024 and 79% in 2023. In retail it did rise to 16% from 14%, but it still remained very low.
Against that backdrop, the 2025 presentation shows the brand segment closing the year with only a 1.1% EBIT margin and a 12.5% EBITDA margin, while retail posted 4.5% and 6.1% respectively. That does not prove Jordan is the only issue. But it does show that the part of the business more exposed to self-manufacturing still did not convert that strategic importance into clean margin in 2025.
| Segment | Self-manufacturing share of sales 2024 | Self-manufacturing share of sales 2025 | 2025 EBIT margin |
|---|---|---|---|
| Brands | 76% | 72% | 1.1% |
| Retail | 14% | 16% | 4.5% |
That is a material point. If the Jordan transition is supposed to earn margin back, it has to change the picture exactly where in-house production is meant to matter most. As of year-end 2025, that evidence is still missing.
Why The Margin Compression Is Not A One-Variable Story
It would be easy to look at the sharp profit decline and conclude that the investment is not working. That would be too fast. The presentation itself says 2025 margin pressure reflected lower volume and operational inefficiencies during the transition. At the same time, the annual filing estimates that the new U.S. tariff regime reduced 2025 profit before tax by about $3 million, including about $1.5 million in the fourth quarter alone. In other words, 2025 is a year of operating noise and external noise at the same time.
That matters because it defines the right test for 2026. If margin improves, it will not be correct to attribute all of that recovery to the Jordan project. Some of it could come from lower tariffs, tariff refunds, better demand, lower SOFR, or simply easier comparisons against a weak base year. To argue that the Jordan investment truly earns back margin, Tefron will need to show improvement that does not depend too heavily on those outside supports.
So far, profitability does not yet show that. EBIT fell to $8.684 million from $23.744 million, and EBIT margin dropped to 3.7% from 8.1%. EBITDA fell to $18.108 million from $34.187 million. This is not only a transition story. But it is also not a year that already proves payback.
Who Funded The Bridge Year
The filing is very clear on this point: operating cash flow in 2025 was $11.018 million, but investing outflow alone was $19.884 million. On top of that came a $2.060 million dividend and $2.876 million of lease-liability repayments. The transition was therefore not funded out of operating cash generation alone.
Note 14 shows how the banking framework was reshaped around the move. Under the Citi financing agreement, annual investments were originally capped at $12 million during the first two years. In mid-2025 the company amended the agreement, raising the 2025 investment cap first to $17 million and then to $21 million. It also raised the in-transit inventory cap used in the borrowing-base formula. At the same time, Tefron took a $10 million term loan at SOFR plus 2.15%, with 48 fixed monthly payments of $85 thousand and a balloon payment in July 2029.
The message runs both ways. On one side, the bank gave the company room to complete the transition. On the other, the amendment itself tells you the project no longer fit inside a normal maintenance envelope. It was a large enough deviation to require the financing documents to be reopened midstream.
At year-end 2025, the company remained in compliance with its covenants, with a debt-service coverage ratio of 1.32 and debt-to-EBITDA of 0.96. This is not a distress setup. But it also does not change the fact that the year was funded through a combination of operating cash, bank credit, supplier credit, and customer advance structures. If the question is whether the investment can truly earn back margin, the real question is whether it can also earn back financial flexibility.
What Has To Happen For The Investment To Earn Back Margin
Four checkpoints will determine whether the Jordan move actually works economically:
First: the relocation into the new facility has to be completed during the second quarter of 2026 without quality slippage and without delivery disruption. The company itself warns that capacity expansion carries a risk of more quality issues during new-worker training.
Second: utilization has to improve, not just nameplate capacity. As long as actual output stays around 13 million units against 23 million of capacity, the room for material operating leverage remains limited.
Third: the move has to lower unit cost or reduce subcontracting fast enough to offset the heavier asset base. Without that, Tefron is simply swapping variable flexibility for a larger fixed platform.
Fourth: the margin improvement has to show up even before large outside tailwinds. Tariff refunds, lower rates, or better demand could help a lot, but they are not proof that the new Jordan facility by itself changed the manufacturing economics.
Bottom Line
The Jordan transition looks strategically logical, but as of year-end 2025 it is still not a proven success. The filing lays out a credible industrial rationale: concentrated production, refreshed machinery, higher efficiency, and lower manufacturing cost. It also shows real balance-sheet commitment: nearly $20 million of cash investment, a financing amendment, and funding capacity explicitly adapted to the project.
But the outcome test is still open. Utilization fell, profitability weakened, and the company does not yet disclose a quantified savings target, a target utilization range, or a payback timetable. For now, the right way to read the move is not as proven margin restoration but as proven intent. 2026 should be the year in which Tefron shows whether that intent can become a cheaper, faster, more efficient production system, or whether it simply built a more expensive infrastructure base into demand that still has not fully recovered.